Illumina Names Susan E. Siegel to Its Board of Directors

Adding Decades of Leadership Experience in Personalized Medicine,
Digital Health and Life Sciences

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that Sue Siegel has joined
the company’s Board of Directors effective February 5, 2019. Ms. Siegel
is Chief Innovation Officer at General Electric (GE) and CEO of GE
Ventures. She is responsible for leading the development and
acceleration of innovation across GE and built GE Ventures, which
invests in promising startups, creates new businesses, commercializes
GE’s intellectual property and catalyzes the development of new markets.

Ms. Siegel has more than 30 years of corporate, entrepreneurial and
venture capital experience. Before joining GE, she was a General Partner
at Mohr Davidow Ventures, where she led investments in personalized
medicine, digital health and life sciences. Prior to that, Ms. Siegel
served as president and board member at Affymetrix, steering the
company’s transformation from a pre-revenue startup to a global genomics
leader with a multibillion-dollar market cap. Earlier, she held
executive positions spanning functional disciplines at Bio-Rad, DuPont
and Amersham.

“Sue is an exceptional innovator who brings significant scientific and
operational experience to our board of directors,” said Francis deSouza,
Illumina President and Chief Executive Officer. “We are excited to have
her creativity and dedication to reimagining healthcare as Illumina
continues its evolution into clinical markets.”

“As a pioneering technology leader, Illumina is advancing many markets,
from life science research to clinical diagnostics to consumer genomics
and beyond, expanding the fast growing yet early genomics economy,” said
Ms. Siegel. “Most importantly, Illumina’s commitment to unlocking the
power of genome through its breakthrough technologies and business
models places it squarely at the forefront of the transformation of
human health. I am thrilled to join the board and eager to support its

Ms. Siegel has served on more than a dozen private and public corporate
boards in her career, including Pacific Biosciences and Affymetrix.
Currently, she is a board member at Align Technologies and MIT’s The
Engine. In addition, she co-chairs Stanford Medicine’s Board of Fellows
and serves on advisory boards for Harvard Partners Healthcare
Innovation, UC Innovation Council, RAND Health Care, and USC Marshall
School Board of Leaders. Her non-profit board appointments have included
the National Venture Capital Association and Silicon Valley’s Tech
Museum of Innovation.

A champion of field-building initiatives that support the advancement of
healthcare research and its translation, Ms. Siegel was a founding
representative member of the National Institutes of Health’s National
Center for Advancing Translational Sciences and served on the Precision
Medicine Initiative Working Group of the Advisory Committee to the NIH
, which led to the creation of All of Us.

A recognized business leader and innovator, Ms. Siegel has been named
one of “34 Leaders Who Are Changing Health Care” by Fortune, one of “The
100 Most Influential Women in Silicon Valley” by Silicon Valley Business
Journal, and among the top five on the Global Corporate Venturing
Powerlist. Ms. Siegel was also featured as a transformational leader in
the book “Multipliers: How The Best Leaders Make Everyone Smarter.” Ms.
Siegel is a Henry Crown Fellow of the Aspen Institute and a member of
YPO-WPO and Women Corporate Directors.

About Illumina

Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit and
follow @illumina.



Illumina, Inc.
Jacquie Ross, CFA

error: Content is protected !!